Patents by Inventor Victor W. Rosso

Victor W. Rosso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210107897
    Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 15, 2021
    Inventors: Ke Chen, Joerg Deerberg, Dong Lin, Michael Dummeldinger, Bahar Inankur, Sergei Kolotuchin, Jun Li, Amanda J. Rogers, Victor W. Rosso, Eric M. Simmons, Maxime C.D. Soumeillant, Daniel S. Treitler, Jianji Wang, Bin Zheng, Michael J. Smith, Neil A. Strotman, Steven Tymonko, Tamas Benkovics
  • Patent number: 10899745
    Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 26, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ke Chen, Joerg Deerberg, Dong Lin, Michael Dummeldinger, Bahar Inankur, Sergei Kolotuchin, Jun Li, Amanda J. Rogers, Victor W. Rosso, Eric M. Simmons, Daniel S. Treitler, Jianji Wang, Michael J. Smith, Tamas Benkovics
  • Publication number: 20200109134
    Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 9, 2020
    Inventors: Ke Chen, Joerg Deerberg, Dong Lin, Michael Dummeldinger, Bahar Inankur, Sergei Kolotuchin, Jun Li, Amanda J. Rogers, Victor W. Rosso, Eric M. Simmons, Maxime C.D. Soumeillant, Daniel S. Treitler, Jianji Wang, Bin Zheng, Michael J. Smith, Neil A. Strotman, Steven Tymonko, Tamas Benkovics
  • Publication number: 20170121295
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Application
    Filed: December 16, 2016
    Publication date: May 4, 2017
    Applicants: AMIRA PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jason Edward BRITTAIN, Thomas Jon SEIDERS, Christopher David KING, Victor W. ROSSO
  • Patent number: 9556133
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: January 31, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, AMIRA PHARMACEUTICALS, INC.
    Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
  • Patent number: 9173879
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: November 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chenkou Wei, Victor W. Rosso, Qi Gao
  • Publication number: 20150183818
    Abstract: The present invention is directed to a process for preparing diastereomerically enriched nucleoside phosphoramidates having the formula I:
    Type: Application
    Filed: July 2, 2013
    Publication date: July 2, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kristy Tran, Martin D. Eastgate, Jacob Janey, Ke Chen, Victor W. Rosso
  • Publication number: 20140364441
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventors: Chenkou Wei, Victor W. Rosso, Qi Gao
  • Patent number: 8815894
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: August 26, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chenkou Wei, Victor W. Rosso, Qi Gao
  • Publication number: 20130253023
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Application
    Filed: December 7, 2011
    Publication date: September 26, 2013
    Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
  • Patent number: 8383812
    Abstract: The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: February 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Victor W. Rosso, Jun Li
  • Publication number: 20130039989
    Abstract: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 14, 2013
    Inventors: Dilbir S. Bindra, Yeshwant Gokhale, Cletus John Nunes, Victor W. Rosso, Gretchen M. Schroeder, Ajit B. Thakur, Xiaotian Yin
  • Publication number: 20110086857
    Abstract: The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.
    Type: Application
    Filed: October 11, 2010
    Publication date: April 14, 2011
    Inventors: Percy H. Carter, Robert J. Cherney, Victor W. Rosso, Jun Li
  • Publication number: 20100292250
    Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 18, 2010
    Applicant: ALBANY MOLECULAR RESEARCH, INC.
    Inventors: CHENKOU WEI, VICTOR W. ROSSO, QI GAO
  • Publication number: 20080275009
    Abstract: Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof.
    Type: Application
    Filed: July 7, 2008
    Publication date: November 6, 2008
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ramakrishnan Chidambaram, George M. Derbin, Masaki Endo, Julia ZH Gao, Tu Lee, Rajeshwar Motheram, William Lawrence Parker, Victor W. Rosso, Sailesh A. Varia
  • Publication number: 20080188517
    Abstract: The instant invention provides crystalline forms of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one and its solvates thereof, processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
    Type: Application
    Filed: April 9, 2008
    Publication date: August 7, 2008
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Mary F. Malley, Roxana Schlam, Steven R. Fabian, Bing-Shiou Yang, Victor W. Rosso
  • Patent number: 7388098
    Abstract: Provided is a dynamic resolution method of enriching a desired isomer of an alpha-substituted carboxylic acid relative to an undesired isomer, the method comprising: (a) in a solvent, contacting the alpha-substituted carboxylic acid, wherein the alpha substitution is with a leaving group and wherein the alpha carbon is chiral, with a homochiral amine to form a salt that is partially insoluble under selected reaction conditions, wherein the homochiral amine is selected so that the solubility of the amine salt of the undesired alpha-substituted carboxylic acid is greater than that of the amine salt of the desired alpha-substituted carboxylic acid under the selected reaction conditions; (b) reacting under the selected reaction conditions the salt with a nucleophile, wherein the reacting is effective in producing a net increase in the less soluble amine salt of the alpha-substituted carboxylic acid, and wherein the selected conditions are selected to (i) promote nucleophilic substitution of the nucleophile and th
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: June 17, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Venit, Gary D. Madding, Victor W. Rosso, Francis J. Okuniewicz, Robert P. Discordia, Susanne Kiau, Atul S. Kotnis, Michael E. Randazzo, D. David Hennings, Jingyang Zhu, Jason G. Chen
  • Patent number: 7371864
    Abstract: The instant invention provides crystalline forms of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: May 13, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Mary F. Malley, Roxana Schlam, Steven R. Fabian, Bing-Shiou Yang, Victor W. Rosso
  • Patent number: 6968037
    Abstract: Multiple samples are prepared in slurry form and deposited through a funnel plate by a multiprobe liquid handler into an array of inserts situated in openings in a housing. Each insert has a recess that extends through the insert body and a filter disc situated in the recess to support the sample. The filter is held in place by an annular part which defines a channel providing access to the filter through the lower portion of the recess. A pressure differential is created across each of the filters by attaching a vacuum manifold to the bottom of the housing to simultaneously remove the liquid from each of the samples, leaving the samples in powder form. The housing is then placed in the X-ray diffractometer for sequential analysis of each of the samples, while the samples are situated in the inserts.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: November 22, 2005
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Victor W. Rosso, Glen Young, Joseph Nolfo, Imre M. Vit z, John J. Venit
  • Patent number: 6893613
    Abstract: The base of the modular reactor includes a frame which defines an opening into which one of a plurality of interchangeable reaction vessel carrying inserts can be removeably received. Each insert has an array of recesses adapted to receive a different number of reaction vessels of different sizes. The recesses are positioned such that all arrays are suitable for use with a standard automated liquid handier. The frame has fluid flow channels for regulating the temperature of the lower portions of the vessels. A temperature control module can be received over the base to regulate the temperature of the upper portions of the vessels for reflux reactions. The corner radii of the insert and frame opening cooperate to permit the insert to be received in the frame in only one orientation. The walls of the insert are inclined to facilitate removal by a friction fit tool.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: May 17, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Walter Ruediger, A. Erik Rubin, Alexander Bertok, Victor W. Rosso, Joseph Nolfo, Harold N. Weller